Fresh tissue samples were collected for ChemoID testing from 40 patients affected by unmethylated-MGMT-promoter GBM, with an overall median age of 53 years (range 24–76), 77% of which were male, all eligible for surgical resection. The gene discussed is MGMT; the disease is glioblastoma.